While tumor positivity for PD-L1 on immunohistochemistry alone was not predictive of patient outcomes [5,22], there was an association between higher melanoma PD-L1 expression scores and improved survival of patients receiving anti-PD-1 monotherapy [23]. The gene discussed is PDCD1; the disease is melanoma.